Autoimmune hepatitis: new guidelines, new therapies

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease with a poor prognosis if untreated.
• Current standard therapy involves corticosteroids and azathioprine to induce remission.
• Early diagnosis is crucial to prevent cirrhosis development.

Purpose of the Study:

• To review the established and emerging treatment strategies for autoimmune hepatitis.
• To address challenges in AIH management, including side effects, nonresponse, and adherence.
• To evaluate alternative therapies and the role of liver transplantation.

Main Methods:

• Review of historical and current treatment protocols for AIH.
• Analysis of challenges in immunosuppressive therapy for AIH.
• Evaluation of outcomes with alternative drugs like budesonide and liver transplantation.

Main Results:

• Corticosteroids and azathioprine remain the cornerstone of AIH treatment.
• Managing side effects, nonresponse, and adherence are significant clinical hurdles.
• Budesonide shows potential for reducing steroid-related side effects in noncirrhotic AIH.
• Liver transplantation is reserved for treatment failures, with a risk of recurrence.

Conclusions:

• While standard therapy is effective, challenges in AIH management persist.
• Budesonide offers a promising alternative for specific patient groups.
• Liver transplantation is a viable option for advanced disease, but recurrence is a concern.